Related Experiment Video
Updated: Jul 3, 2025
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer
Shaikh Samia1, Padakanti Sandeep Chary1, Omar Khan1
1Pharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India.
Abstract:
Breast cancer (BC) remains a significant health burden worldwide, necessitating the development of innovative therapeutic strategies. The B-cell lymphoma 2 (Bcl-2) family proteins, Bcl-2 and Bax, play a crucial role in regulating apoptosis and thus are promising targets for BC therapy. We focus on the recent advancements in novel formulations that specifically target Bcl-2/Bax pathway to combat BC. It provides an overview on biological functions of Bcl-2/Bax in apoptosis regulation, emphasizing their significance in pathogenesis and progression of the disease while covering the numerous therapeutic approaches aimed at modulating the Bcl-2/Bax pathway, including small-molecule inhibitors, peptides, gene-based therapies and other repurposed drugs harboured onto cutting-edge technologies and nanocarrier systems employed to enhance the targeted delivery of Bcl-2/Bax inhibitors tumor cells. These advanced formulations aim to improve therapeutic efficacy, minimize off-target effects, and overcome drug resistance, offering promising prospects in its treatment. In conclusion, it illuminates the diverse and evolving landscape of novel formulations as an essential armament in targeting these proteins while bridging and unravelling the obscurity of Bcl-2/Bax pathway-targeted drug delivery systems which are presently in their nascent stages of exploration for BC therapy which can benefit researchers, clinicians, and pharmaceutical scientists.
Insights
Novel drug formulations targeting the B-cell lymphoma 2 (Bcl-2)/Bax pathway offer new hope for breast cancer (BC) treatment. These advanced delivery systems aim to improve efficacy and reduce side effects in BC therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Delivery Systems
Background:
- Breast cancer (BC) poses a significant global health challenge, driving the need for advanced therapeutic strategies.
- The B-cell lymphoma 2 (Bcl-2) protein family, including Bcl-2 and Bax, are key regulators of apoptosis and critical targets in BC.
- Dysregulation of the Bcl-2/Bax pathway is implicated in BC pathogenesis and progression.
Purpose of the Study:
- To review recent advancements in novel formulations targeting the Bcl-2/Bax pathway for breast cancer therapy.
- To provide an overview of the biological roles of Bcl-2/Bax in apoptosis and their significance in BC.
- To explore various therapeutic approaches and drug delivery systems for modulating the Bcl-2/Bax pathway.
Main Methods:
- Review of current literature on Bcl-2/Bax pathway inhibitors and drug delivery systems.
- Analysis of small-molecule inhibitors, peptides, gene-based therapies, and repurposed drugs.
- Examination of nanocarrier systems and cutting-edge technologies for targeted delivery.
Main Results:
- Various therapeutic strategies, including small-molecule inhibitors and gene-based therapies, are being developed to target the Bcl-2/Bax pathway.
- Cutting-edge technologies and nanocarrier systems enhance the targeted delivery of Bcl-2/Bax inhibitors to tumor cells.
- Advanced formulations aim to improve therapeutic efficacy, minimize off-target effects, and overcome drug resistance in BC.
Conclusions:
- Novel formulations targeting the Bcl-2/Bax pathway represent a promising frontier in breast cancer treatment.
- Targeted drug delivery systems are crucial for enhancing the efficacy of Bcl-2/Bax inhibitors.
- Further research into these nascent drug delivery systems is essential for advancing BC therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31The Intrinsic Apoptotic Pathway
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:15Drugs that Stabilize Microtubules